Van Cutsem, E., Collignon, J., Eefsen, R. L., Ochsenreither, S., Zvirbule, Z., Ivanauskas, A., . . . Awada, A. (2024). Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer. Clinical Cancer Research, 30, 5293. https://doi.org/10.1158/1078-0432.ccr-24-0645
Citácia podle Chicago (17th ed.)Van Cutsem, Eric, et al. "Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer." Clinical Cancer Research 30 (2024): 5293. https://doi.org/10.1158/1078-0432.ccr-24-0645.
Citácia podľa MLA (8th ed.)Van Cutsem, Eric, et al. "Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer." Clinical Cancer Research, vol. 30, 2024, p. 5293, https://doi.org/10.1158/1078-0432.ccr-24-0645.